vs

Side-by-side financial comparison of OneSpan Inc. (OSPN) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $65.9M, roughly 1.1× OneSpan Inc.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 4.1%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 4.0%).

OneSpan Inc. is an information security company based in Boston, Massachusetts. Services include an internet fraud prevention platform, multi-factor authentication tools and electronic signature software.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

OSPN vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.1× larger
PBYI
$75.5M
$65.9M
OSPN
Growing faster (revenue YoY)
PBYI
PBYI
+23.6% gap
PBYI
27.7%
4.1%
OSPN
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
4.0%
OSPN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
OSPN
OSPN
PBYI
PBYI
Revenue
$65.9M
$75.5M
Net Profit
$11.6M
Gross Margin
73.6%
69.3%
Operating Margin
22.5%
22.7%
Net Margin
17.5%
Revenue YoY
4.1%
27.7%
Net Profit YoY
EPS (diluted)
$0.39
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OSPN
OSPN
PBYI
PBYI
Q1 26
$65.9M
Q4 25
$62.9M
$75.5M
Q3 25
$57.1M
$54.5M
Q2 25
$59.8M
$52.4M
Q1 25
$63.4M
$46.0M
Q4 24
$61.2M
$59.1M
Q3 24
$56.2M
$80.5M
Q2 24
$60.9M
$47.1M
Net Profit
OSPN
OSPN
PBYI
PBYI
Q1 26
$11.6M
Q4 25
$43.5M
Q3 25
$6.5M
$8.8M
Q2 25
$8.3M
$5.9M
Q1 25
$14.5M
$3.0M
Q4 24
$28.8M
Q3 24
$8.3M
$20.3M
Q2 24
$6.6M
$-4.5M
Gross Margin
OSPN
OSPN
PBYI
PBYI
Q1 26
73.6%
Q4 25
73.6%
69.3%
Q3 25
73.6%
77.7%
Q2 25
73.5%
76.5%
Q1 25
74.3%
77.1%
Q4 24
74.0%
76.4%
Q3 24
73.9%
63.9%
Q2 24
66.2%
77.4%
Operating Margin
OSPN
OSPN
PBYI
PBYI
Q1 26
22.5%
Q4 25
19.9%
22.7%
Q3 25
14.4%
17.6%
Q2 25
17.6%
12.7%
Q1 25
27.1%
8.7%
Q4 24
19.3%
22.6%
Q3 24
20.0%
27.4%
Q2 24
12.5%
-4.6%
Net Margin
OSPN
OSPN
PBYI
PBYI
Q1 26
17.5%
Q4 25
69.2%
Q3 25
11.4%
16.2%
Q2 25
13.9%
11.2%
Q1 25
22.9%
6.5%
Q4 24
47.1%
Q3 24
14.7%
25.2%
Q2 24
10.8%
-9.6%
EPS (diluted)
OSPN
OSPN
PBYI
PBYI
Q1 26
$0.39
Q4 25
$1.13
$0.26
Q3 25
$0.17
$0.17
Q2 25
$0.21
$0.12
Q1 25
$0.37
$0.06
Q4 24
$0.73
$0.40
Q3 24
$0.21
$0.41
Q2 24
$0.17
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OSPN
OSPN
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$49.8M
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$272.0M
$130.3M
Total Assets
$383.1M
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OSPN
OSPN
PBYI
PBYI
Q1 26
$49.8M
Q4 25
$70.5M
$97.5M
Q3 25
$85.6M
$94.4M
Q2 25
$92.9M
$96.0M
Q1 25
$105.2M
$93.2M
Q4 24
$83.2M
$101.0M
Q3 24
$77.5M
$96.7M
Q2 24
$63.8M
$96.8M
Total Debt
OSPN
OSPN
PBYI
PBYI
Q1 26
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Stockholders' Equity
OSPN
OSPN
PBYI
PBYI
Q1 26
$272.0M
Q4 25
$271.8M
$130.3M
Q3 25
$238.3M
$115.3M
Q2 25
$242.5M
$104.7M
Q1 25
$231.1M
$97.1M
Q4 24
$212.5M
$92.1M
Q3 24
$194.6M
$71.1M
Q2 24
$178.6M
$48.5M
Total Assets
OSPN
OSPN
PBYI
PBYI
Q1 26
$383.1M
Q4 25
$397.7M
$216.3M
Q3 25
$343.5M
$202.9M
Q2 25
$357.1M
$194.9M
Q1 25
$333.8M
$196.2M
Q4 24
$338.7M
$213.3M
Q3 24
$289.3M
$220.7M
Q2 24
$286.9M
$205.0M
Debt / Equity
OSPN
OSPN
PBYI
PBYI
Q1 26
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OSPN
OSPN
PBYI
PBYI
Operating Cash FlowLast quarter
$28.2M
$14.4M
Free Cash FlowOCF − Capex
$14.4M
FCF MarginFCF / Revenue
19.1%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
2.44×
TTM Free Cash FlowTrailing 4 quarters
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OSPN
OSPN
PBYI
PBYI
Q1 26
$28.2M
Q4 25
$12.6M
$14.4M
Q3 25
$11.3M
$9.7M
Q2 25
$6.2M
$14.1M
Q1 25
$29.4M
$3.6M
Q4 24
$12.4M
$15.6M
Q3 24
$14.0M
$11.0M
Q2 24
$2.3M
$1.0M
Free Cash Flow
OSPN
OSPN
PBYI
PBYI
Q1 26
Q4 25
$9.6M
$14.4M
Q3 25
$8.8M
$9.7M
Q2 25
$4.4M
$14.1M
Q1 25
$27.7M
$3.6M
Q4 24
$10.5M
$15.6M
Q3 24
$12.0M
$11.0M
Q2 24
$26.0K
$1.0M
FCF Margin
OSPN
OSPN
PBYI
PBYI
Q1 26
Q4 25
15.3%
19.1%
Q3 25
15.4%
17.7%
Q2 25
7.3%
26.8%
Q1 25
43.8%
7.7%
Q4 24
17.1%
26.4%
Q3 24
21.4%
13.7%
Q2 24
0.0%
2.1%
Capex Intensity
OSPN
OSPN
PBYI
PBYI
Q1 26
Q4 25
4.7%
0.0%
Q3 25
4.4%
0.0%
Q2 25
3.1%
0.0%
Q1 25
2.6%
0.1%
Q4 24
3.2%
0.0%
Q3 24
3.5%
0.0%
Q2 24
3.7%
0.0%
Cash Conversion
OSPN
OSPN
PBYI
PBYI
Q1 26
2.44×
Q4 25
0.29×
Q3 25
1.74×
1.10×
Q2 25
0.75×
2.41×
Q1 25
2.02×
1.21×
Q4 24
0.43×
Q3 24
1.69×
0.54×
Q2 24
0.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OSPN
OSPN

Product and license$35.5M54%
Services and other$30.4M46%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons